A rugged and accurate liquid chromatography-tandem mass spectrometry method for the determination of asunaprevir, an NS3 protease inhibitor, in plasma

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 921-922, Issue , 2013, Pages 81-86

  Yuan, Long ^a   Jiang, Hao ^a   Ouyang, Zheng ^a   Xia, Yuan Qing ^a,b   Zeng, Jianing ^a   Peng, Qianping ^a   Lange, Robert W ^a   Deng, Yuzhong ^a,c   Arnold, Mark E ^a   Aubry, Anne Françoise ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b MDS SCIEX   (Canada)

^c GENENTECH INC   (United States)

Author keywords

Asunaprevir; BMS 650032; Hepatitis C virus (HCV); LC MS MS; Quantitative

Indexed keywords

ASUNAPREVIR; BMS-650032; HEPATITIS C VIRUS; LC-MS/MS; QUANTITATIVE;

HEXANE; ISOTOPES; LINEAR REGRESSION; LIQUID CHROMATOGRAPHY; OPTIMIZATION; VIRUSES;

MASS SPECTROMETRY;

ASUNAPREVIR;

ACCURACY; ANIMAL EXPERIMENT; ARTICLE; DOG; DRUG DETERMINATION; HAPLORHINI; LIQUID CHROMATOGRAPHY; MOUSE; NONHUMAN; PLASMA; PRIORITY JOURNAL; RABBIT; RAT; TANDEM MASS SPECTROMETRY;

ANIMALS; ANTIVIRAL AGENTS; CHROMATOGRAPHY, LIQUID; DOGS; HAPLORHINI; HEPACIVIRUS; HEPATITIS C; ISOQUINOLINES; MICE; PROTEASE INHIBITORS; RABBITS; RATS; SENSITIVITY AND SPECIFICITY; SULFONAMIDES; TANDEM MASS SPECTROMETRY; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84874580473     PISSN: 15700232     EISSN: 1873376X     Source Type: Journal    
DOI: 10.1016/j.jchromb.2013.01.029     Document Type: Article

References (15)

1. Hepatology 2002, 36(5 I):S3.
2. Ghany M.G., Strader D.B., Thomas D.L., Seeff L.B. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49(4):1335.
3. Bartenschlager R., Lohmann V., Wilkinson T., Koch J.O. Complex formation between the NS3 serine-type proteinase of the hepatitis C virus and NS4A and its importance for polyprotein maturation. J. Virol. 1995, 69(12):7519.
4. Asselah T., Marcellin P. Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow. Liver Int. 2012, 32(Suppl. 1):88.
5. Pasquinelli C., McPhee F., Eley T., et al. Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C. Antimicrob. Agents Chemother. 2012, 56(4):1838.
6. Jiang H., Zeng J., Zheng N., et al. A convenient strategy for quantitative determination of drug concentrations in tissue homogenates using a liquid chromatography/tandem mass spectrometry assay for plasma samples. Anal. Chem. 2011, 83(16):6237.
7. Jemal M., Ouyang Z., Xia Y.Q. Systematic LC-MS/MS bioanalytical method development that incorporates plasma phospholipids risk avoidance, usage of incurred sample and well thought-out chromatography. Biomed. Chromatogr. 2010, 24(1):2.
8. Jiang H., Zeng J., Deng Y., et al. A rugged and accurate liquid chromatography-tandem mass spectrometry method for quantitative determination of BMS-790052 in plasma. J. Chromatogr. B 2011, 879(22):2064.
9. Matuszewski B.K., Constanzer M.L., Chavez-Eng C.M. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal. Chem. 2003, 75(13):3019.
10. Taylor P.J. Matrix effects: the Achilles heel of quantitative high-performance liquid chromatography-electrospray-tandem mass spectrometry. Clin. Biochem. 2005, 38(4):328.
11. Xia Y.Q., Jemal M. Phospholipids in liquid chromatography/mass spectrometry bioanalysis: Comparison of three tandem mass spectrometric techniques for monitoring plasma phospholipids, the effect of mobile phase composition on phospholipids elution and the association of phospholipids with matrix effects. Rapid Commun. Mass Spectrom. 2009, 23(14):2125.
12. Tong X.S., Wang J., Zheng S., et al. Effect of signal interference from dosing excipients on pharmacokinetics screening of drug candidates by liquid chromatography/mass spectrometry. Anal. Chem. 2002, 74(24):6305.
13. Xu X., Mei H., Wang S., et al. A study of common discovery dosing formulation components and their potential for causing time-dependent matrix effects in high-performance liquid chromatography tandem mass spectrometry assays. Rapid Commun. Mass Spectrom. 2005, 19(18):2643.
14. Shou W.Z., Naidong W. Post-column infusion study of the 'dosing vehicle effect' in the liquid chromatography/tandem mass spectrometric analysis of discovery pharmacokinetics samples. Rapid Commun. Mass Spectrom. 2003, 17(6):589.
15. Guidance for Industry: Bioanalytical Method Validation. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf.